Carregant...
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4839356/ https://ncbi.nlm.nih.gov/pubmed/27141345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1088631 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|